Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Income from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares OutstandingShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

Lisata Therapeutics (LSTA) Operating Income (2016 - 2025)

Lisata Therapeutics' Operating Income history spans 13 years, with the latest figure at -$3.1 million for Q4 2025.

  • For Q4 2025, Operating Income rose 37.79% year-over-year to -$3.1 million; the TTM value through Dec 2025 reached -$18.2 million, up 18.75%, while the annual FY2025 figure was -$18.2 million, 18.74% up from the prior year.
  • Operating Income reached -$3.1 million in Q4 2025 per LSTA's latest filing, up from -$4.4 million in the prior quarter.
  • In the past five years, Operating Income ranged from a high of -$3.1 million in Q4 2025 to a low of -$6.9 million in Q2 2023.
  • Average Operating Income over 3 years is -$5.5 million, with a median of -$5.7 million recorded in 2024.
  • Peak YoY movement for Operating Income: grew 3.55% in 2024, then skyrocketed 37.79% in 2025.
  • A 3-year view of Operating Income shows it stood at -$6.0 million in 2023, then rose by 17.86% to -$4.9 million in 2024, then surged by 37.79% to -$3.1 million in 2025.
  • Per Business Quant, the three most recent readings for LSTA's Operating Income are -$3.1 million (Q4 2025), -$4.4 million (Q3 2025), and -$4.9 million (Q2 2025).